These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 27256275

  • 1. Morphological features that can predict BRAFV600E -mutated carcinoma in paediatric thyroid cytology.
    Rossi ED, Bizzarro T, Martini M, Capodimonti S, Cenci T, Fadda G, Schmitt F, Larocca LM.
    Cytopathology; 2017 Feb; 28(1):55-64. PubMed ID: 27256275
    [Abstract] [Full Text] [Related]

  • 2. Morphological parameters able to predict BRAF(V600E) -mutated malignancies on thyroid fine-needle aspiration cytology: Our institutional experience.
    Rossi ED, Bizzarro T, Martini M, Capodimonti S, Fadda G, Larocca LM, Schmitt F.
    Cancer Cytopathol; 2014 Dec; 122(12):883-91. PubMed ID: 25156883
    [Abstract] [Full Text] [Related]

  • 3. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
    Rossi ED, Martini M, Bizzarro T, Capodimonti S, Cenci T, Lombardi CP, Pontecorvi A, Fadda G, Larocca LM.
    Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
    [Abstract] [Full Text] [Related]

  • 4. The expression of monocarboxylate transporters in thyroid carcinoma can be associated with the morphological features of BRAF V600E mutation.
    Rossi ED, Bizzarro T, Granja S, Martini M, Capodimonti S, Luca E, Fadda G, Lombardi CP, Pontecorvi A, Larocca LM, Baltazar F, Schmitt F.
    Endocrine; 2017 May; 56(2):379-387. PubMed ID: 27484771
    [Abstract] [Full Text] [Related]

  • 5. Immunohistochemistry for BRAF(V600E) antibody VE1 performed in core needle biopsy samples identifies mutated papillary thyroid cancers.
    Crescenzi A, Guidobaldi L, Nasrollah N, Taccogna S, Cicciarella Modica DD, Turrini L, Nigri G, Romanelli F, Valabrega S, Giovanella L, Onetti Muda A, Trimboli P.
    Horm Metab Res; 2014 May; 46(5):370-4. PubMed ID: 24570209
    [Abstract] [Full Text] [Related]

  • 6. Detection of BRAF c.1799T > A (p.V600E) mutation using residual routine fine-needle aspiration specimens of papillary thyroid carcinoma.
    Zhao H, Zhang ZH, Zhou B, Xiao T, Pan QJ, Guo HQ.
    Diagn Cytopathol; 2015 Oct; 43(10):786-90. PubMed ID: 26152656
    [Abstract] [Full Text] [Related]

  • 7. When Morphology Meets Somatic Mutations: The New Possible Scenario in Thyroid Fine-Needle Aspiration.
    Rossi ED, Schmitt F.
    Acta Cytol; 2016 Oct; 60(2):93-6. PubMed ID: 27288325
    [Abstract] [Full Text] [Related]

  • 8. Detection of the BRAF(V600E) mutation in fine needle aspiration cytology of thyroid papillary microcarcinoma cells selected by manual macrodissection: an easy tool to improve the preoperative diagnosis.
    Marchetti I, Iervasi G, Mazzanti CM, Lessi F, Tomei S, Naccarato AG, Aretini P, Alberti B, Di Coscio G, Bevilacqua G.
    Thyroid; 2012 Mar; 22(3):292-8. PubMed ID: 22181337
    [Abstract] [Full Text] [Related]

  • 9. BRAF (V600E) mutation analysis on liquid-based cytology-processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma.
    Rossi ED, Martini M, Capodimonti S, Lombardi CP, Pontecorvi A, Vellone VG, Zannoni GF, Larocca LM, Fadda G.
    Cancer Cytopathol; 2013 Jun; 121(6):291-7. PubMed ID: 23192956
    [Abstract] [Full Text] [Related]

  • 10. Pilot of BRAF mutation analysis in indeterminate, suspicious and malignant thyroid FNA cytology.
    Johnson SJ, Hardy SA, Roberts C, Bourn D, Mallick U, Perros P.
    Cytopathology; 2014 Jun; 25(3):146-54. PubMed ID: 24417615
    [Abstract] [Full Text] [Related]

  • 11. Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays.
    Ilie MI, Lassalle S, Long-Mira E, Bonnetaud C, Bordone O, Lespinet V, Lamy A, Sabourin JC, Haudebourg J, Butori C, Guevara N, Peyrottes I, Sadoul JL, Bozec A, Santini J, Capper D, von Deimling A, Emile JF, Hofman V, Hofman P.
    Thyroid; 2014 May; 24(5):858-66. PubMed ID: 24417277
    [Abstract] [Full Text] [Related]

  • 12. BRAF mutation testing of thyroid fine-needle aspiration specimens enhances the predictability of malignancy in thyroid follicular lesions of undetermined significance.
    Adeniran AJ, Hui P, Chhieng DC, Prasad ML, Schofield K, Theoharis C.
    Acta Cytol; 2011 May; 55(6):570-5. PubMed ID: 22156468
    [Abstract] [Full Text] [Related]

  • 13. BRAF mutation analysis of fine-needle aspiration biopsies of papillary thyroid carcinoma: impact on diagnosis and prognosis.
    Colanta A, Lin O, Tafe L, Ghossein R, Nafa K, Mitchell T, Ladanyi M, Arcila M.
    Acta Cytol; 2011 May; 55(6):563-9. PubMed ID: 22156467
    [Abstract] [Full Text] [Related]

  • 14. Diagnostic and prognostic value of immunocytochemistry and BRAF mutation analysis on liquid-based biopsies of thyroid neoplasms suspicious for carcinoma.
    Rossi ED, Martini M, Capodimonti S, Straccia P, Cenci T, Lombardi CP, Pontecorvi A, Larocca LM, Fadda G.
    Eur J Endocrinol; 2013 Jun; 168(6):853-9. PubMed ID: 23513230
    [Abstract] [Full Text] [Related]

  • 15. Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma.
    Koperek O, Kornauth C, Capper D, Berghoff AS, Asari R, Niederle B, von Deimling A, Birner P, Preusser M.
    Am J Surg Pathol; 2012 Jun; 36(6):844-50. PubMed ID: 22592144
    [Abstract] [Full Text] [Related]

  • 16. Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma.
    Zhu X, Luo Y, Bai Q, Lu Y, Lu Y, Wu L, Zhou X.
    Exp Mol Pathol; 2016 Feb; 100(1):236-41. PubMed ID: 26795218
    [Abstract] [Full Text] [Related]

  • 17. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States.
    Prasad ML, Vyas M, Horne MJ, Virk RK, Morotti R, Liu Z, Tallini G, Nikiforova MN, Christison-Lagay ER, Udelsman R, Dinauer CA, Nikiforov YE.
    Cancer; 2016 Apr 01; 122(7):1097-107. PubMed ID: 26784937
    [Abstract] [Full Text] [Related]

  • 18. Use of BRAF v600e immunocytochemistry on FNA direct smears of papillary thyroid carcinoma.
    Wobker SE, Kim LT, Hackman TG, Dodd LG.
    Cancer Cytopathol; 2015 Sep 01; 123(9):531-9. PubMed ID: 26080065
    [Abstract] [Full Text] [Related]

  • 19. [Association of BRAF(V) 600E mutation with clinical pathological features in papillary thyroid carcinoma: meta-analysis].
    Yan K, Lin X, Li S, Bao H, Zhao L, Liu X.
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2014 Sep 01; 49(9):759-64. PubMed ID: 25487587
    [Abstract] [Full Text] [Related]

  • 20. Nuclear morphometric findings in undetermined cytology: A possible clue for prediction of BRAF mutation in papillary thyroid carcinomas.
    Mungan S, Ersoz S, Saygin I, Sagnak Z, Cobanoglu U.
    Endocr Res; 2017 May 01; 42(2):138-144. PubMed ID: 27911099
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.